FDA Clears GSK’s Requip XL For Parkinson’s
This article was originally published in The Pink Sheet Daily
Once-daily version is designed to battle generic competitors.
You may also be interested in...
Teva, Mylan, Roxane and Par will market ropinirole for Restless Legs Syndrome; Parkinson's patent expires this month, too.
FDA needs additional time to review food effect data from GlaxoSmithKline for the once-daily Parkinson's treatment.
U.K. drug maker also is planning to initiate a Phase III program evaluating GSK 1838262 for migraine prophylaxis.